INTRODUCTION The glomerular filtration rate (GFR), a measure of renal function, decreases by approximately 10 mL/min every 10 years after the age of 40 years, which could lead to the accumulation of drugs and/or renal toxicity. Pharmacokinetic studies of drugs excreted both renally and non-renally are desirable in patients with impaired renal function, defined by parameters including estimated ...

BACKGROUND In Huntington disease (HD) patients receiving rivastigmine treatment improvement of behavioral symptoms and of cognitive function (assessed with screening diagnostic instruments) has been reported. The aim of the present study was to verify such improvement in cognitive function by cognitive function assessment with a detailed neuropsychological battery covering all relevant cognitiv...

OBJECTIVES To determine the respective efficacy of quetiapine and rivastigmine for agitation in people with dementia in institutional care and to evaluate these treatments with respect to change in cognitive performance. DESIGN Randomised double blind (clinician, patient, outcomes assessor) placebo controlled trial. SETTING Care facilities in the north east of England. PARTICIPANTS 93 pat...

BACKGROUND Oral cholinesterase inhibitors at doses efficacious for the treatment of Alzheimer's disease (AD) are often prematurely discontinued due to gastrointestinal side effects. In controlled clinical trials, transdermal rivastigmine demonstrated less such effects at similar efficacy. The current study aimed to verify the validity of this data in daily practice. METHODS This was a prospec...

BACKGROUND Cholinergic deficits are prominent in patients who have dementia associated with Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor rivastigmine in such patients. METHODS Patients in whom mild-to-moderate dementia developed at least 2 years after they received a clinical diagnosis of Parkinson's disease were randomly assigned to receive placebo or...

OBJECTIVE To compare levels of persistency with 2 cholinesterase (ChE) inhibitors--rivastigmine and donepezil--for the treatment of Alzheimer's disease (AD) through the use of administrative claims data. METHODS This retrospective cohort study identified treatment-naive, community-based AD patients having an initial prescription (index event) for rivastigmine or donepezil between June and Dec...

alzheimer's disease is considered the most common cause of dementia. at present, no definite cure is available for healing the disorders and stopping the disease progress. the aim of this study is to study the effects of piracetam, rivastigmine and their joint consumption on mmse score status in patients with alzheimer disease. this interventional study was carried out on 64 patients with alzhe...

Objectives: Cognitive dysfunction in patients with hepatic encephalopathy (HE) may be caused by alterations in cholinergic neurotransmission. The objective of the study was to evaluate the efficacy and safety of transdermal rivastigmine in improving cognitive function in patients with overt HE. Design: Randomized, controlled pilot study in which patients with grade 2 or 3 HE were treated with l...

Current palliative pharmacotherapy of Alzheimer’s disease based on the cholinergic hypothesisled to the development of four cholinesterase inhibitors. These compounds can bring prolongationof the symptom-free period in some patients. This is the frst report directly comparing donepeziland rivastigmine plasma and brain levels in <span class="font...

Current palliative pharmacotherapy of Alzheimer’s disease based on the cholinergic hypothesisled to the development of four cholinesterase inhibitors. These compounds can bring prolongationof the symptom-free period in some patients. This is the frst report directly comparing donepeziland rivastigmine plasma and brain levels in <span class="font...